National Institutes of Health NIDA
FederalMD
Posted
Sep 8, 2026
Closes
Sep 15, 2026
Pharmacogenomic Analysis of Participants Enrolled in the STAR-B Randomized Clinical Trial of Semaglutide for Alcohol Use Disorder
The National Institutes of Health, through NIDA, seeks genomic laboratory and bioinformatics services for pharmacogenomic analysis of biospecimens from participants in STAR-B, a randomized clinical trial of semaglutide for alcohol use disorder. Work includes specimen receipt and tracking, DNA extraction and quality control, genome-wide genotyping and/or sequencing, bioinformatic processing, and delivery of raw, processed, annotated, and documented data. The special notice identifies Baltimore, Maryland as the place of performance, provides a 12-month period of performance, and requests responses by September 15, 2026 at 3:00 p.m. EDT.
